M. Mendel Shemtov, M.D.

Urology
M. Shemtov

View Dr. Shemtov's Video Introduction

Appointments:

Aug 2006-Present: Associate Professor of Clinical Urology

Associate Attending Urologist

New York Presbyterian Hospital

Cornell University-Weill Medical College

May 2000-Present: Associate Residency Director

Department of Urology

New York Presbyterian Hospital

Cornell University-Weill Medical College

July 2000-July 2006: Assistant Professor of Urology

Assistant Attending Urologist

New York Presbyterian Hospital

Cornell University-Weill Medical College

July 1997-June 2000: Instructor, Department of Urology

Assistant Attending Urologist

New York Presbyterian Hospital

Cornell University-Weill Medical College

Jan 1998-June 2003: Attending, Consultative Services-Urology

Coler-Goldwater Memorial Hospital

Roosevelt Island, New York

May 2000-June 2004: Site Director, Primary Care Clerkship-Urology

New York Presbyterian Hospital

Cornell University-Weill Medical College

May 2000-Dec 2000: Consultant, Prostate Cancer Research

Strang Cancer Prevention Center

Education:

1985-1989 University of Pennsylvania School of Medicine

Philadelphia, Pennsylvania

Doctor of Medicine, 1989

1983-1984 Temple University

Philadelphia, Pennsylvania

Post-baccalaureate Premedical coursework

1980-1983 Rabbinical College of America

Morristown, New Jersey

Bachelor of Arts, 1983

Post Doctoral Training:

1995-1997 Fellow, Urologic Oncology

The New York Hospital-Cornell University Medical Center

New York, New York

1994-1995 Chief Resident, Urology

The Mount Sinai Medical Center

New York, New York

1991-1994 Resident, Urology

The Mount Sinai Medical Center

New York, New York

1989-1991 Intern and Resident, General Surgery

The Mount Sinai Medical Center

New York, New York

Professional Societies and Memberships:

American Urological Association, Active member

New York Section, American Urological Association

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [Medicare]
  • AETNA [PPO]
  • Aetna - Weill Cornell [POS]
  • Affinity Health Plan
  • CIGNA
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Fidelis Care
  • Health First
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Plus - Amerigroup
  • Medicare [Medicare]
  • Rockefeller University - CoreSource
  • United Health Care

Publications

 Droller MJ and Shemtov MM: Quality of Life Issues in Late Stage Prostate Cancer.

Controversies in the Management of Prostate Cancer, Part 6: 1991

 Shemtov MM, Cheng DL, Shu W, Droller MJ and Liu BCS: LAK Cell Killing of Human T24 Bladder Cancer Cells Occurs Via Apoptosis: Possible Mechanism of Intravesical BCG Therapy. Surgical Forum 44:778-780, 1993

 Shemtov MM, Cheng DL, Kong L, Sassoroli M, Droller MJ and Liu BCS: LAK Cell Mediated Apoptosis of Human Bladder Cancer Cells Involves a pH Dependent Endonuclease System in the Cancer Cell: Possible Mechanism of BCG Therapy. Journal of Urology 154:269-274, 1995.

 Shemtov MM and Bander NH: Immunological Approaches to Genitourinary Malignancies. Campbell’s Urology, Sixth Edition: Update, 1996.

 Shemtov MM: Monoclonal Antibodies. AUA Update Series 1998; Vol XVII, Lesson 32.

 Dasari N, Nori D, Vaughan ED, Parikh S, Shemtov MM, Allbright RM, Poli J, Presser J and Osian A: Positive Biopsies and Biochemical Outcome after Combined External Beam Radiation Therapy and Outpatient Conformal Brachytherapy for Clinically Localized Prostate Cancer. Radiology 225: 365-366, 2002.

 Nori D, Reddy NMS, Vaughan ED and Shemtov MM: The Impact of Technological Advances on the Evolution of 3D Conformal Brachytherapy for Early prostate Cancer. Technology in Cancer Research and Treatment 3: 335-345, 2004.

 Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, Nanus D and Menon M: Long Term Survival in Men With High Grade Prostate Cancer: A Comparison Between Conservative Treatment, Radiation Therapy and Radical Prostatectomy – A Propensity Scoring Approach. J Urology 177 (3): 911-5, 2007.

 Schwartz MJ, Hwang DH, Hung AJ, Han J, McClain JW, Shemtov MM, Te AE, Sosa RE, Vaughan ED and Scherr DS: Negative Influence of Changing Biopsy Practice Patterns on the Predictive Value of Prostate Specific Antigen for Prostate Cancer. Cancer 112(8):1718-25, 2008.

 

Abstracts:

 Shemtov MM, Cheng DL, Shu W, Droller MJ and Liu BCS: LAK Cell Killing of Human T24 Bladder Cancer Cells Occurs Via Apoptosis and Involves LAK Cell Membrane Fibronectin Molecule: Possible Mechanism of Intravesical BCG Therapy. (Abstract) Journal of Urology 149:271A, 1993.

 

Shemtov MM, Kong L, Cheng DL, Sassaroli M, Droller MJ, and Liu BCS: LAK Cell Mediated Apoptosis of Human Bladder Cancer Cells Involves a pH Dependent Endonuclease System in the Cancer Cell: Possible Mechanism of BCG Therapy. (Abstract) Journal of Urology 151:225A, 1994.

 Stone NN, Shemtov MM and Thall E: Laparoscopic Orchiopexy of Intraabdominal Testis. (Videotape Abstract) Journal of Urology 151:225A, 1994.

 Shemtov MM and Bander NH. Subcutaneous IL-2 Plus Melatonin in Advanced Prostate Cancer. Submitted American Urological Association Meeting, 1997.

 Shemtov MM: Phase I/II Trial of Monoclonal Antibody (mAb) Prost 30 in Advanced Prostate Cancer. (Abstract) Journal of Urology 157:322A, 1997.

 Dasari N, Nori D, Vaughan ED Jr., Parikh S, Shemtov MM , Poli JMR, Pressor J and Osian A. Role of Combined External Beam Radiation Therapy and Outpatient Conformal Brachytherapy for Clinically Localized Prostate Cancer. Submitted American Brachytherapy Society Meeting, 2001.

 Dasari N, Nori D, Vaughan ED Jr., Parikh S, Shemtov MM, Poli JMR and Allbright RM. Percent Positive Biopsies and Biochemical Outcome After Combined External Beam Radiation Therapy and Outpatient Conformal Brachytherapy for Clinically Localized Prostate Cancer. American Society of Therapeutic Radiation Oncology, 2002.

 Tewari A, Dasari R, El-Hakim A, Divine G, Shemtov MM, Porter CR, Gamito EJ, Schlegel PN, Menon M. High-grade Prostate Cancer: What is the Best Treatment Approach? (Abstract) Journal of Urology 2005; 173: 465A.

 Hung AJ, Schwartz MJ, Hwang DH, McClain JW, Han J, Shemtov MM, Te AE, Sosa RE, Vaughan ED and Scherr DS. Changes in Practice Patterns and Outcomes of Transrectal Ultrasound Guided Prostate Biopsy. J Urology 177(4) 203A, 2007.

 Tu JJ, Jhaveri JK, Yadav R, Leung RA, Te AE, Shemtov MM, et al. Cancer Control Outcomes Following Radical Prostatectomy. A Comparison Between Robotic and Open. Abstract #393. Accepted for Presentation During the 23rd Annual European Association of Urology Congress.

Honors and Awards

Awards:

   First Prize, Laboratory Research

   American Urological Association National Essay Contest: 1994

   Honorable Mention, Laboratory-Formal Research

   Ferdinand C. Valentine Essay Contest

   New York Academy of Medicine: 1994

   Second Prize, Laboratory-Formal Research

   Ferdinand C. Valentine Essay Contest

   New York Academy of Medicine: 1993